A Chronic Cough Pipeline in a Product: Haduvio™
INDICATIONS
Preclinical
Phase 1
Phase 2
Phase 3
Haduvio (nalbuphine ER)
Preclinical
Phase 1
Phase 2
Phase 3
Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
- 70%
Refractory Chronic Cough (RCC)
- 60%
Haduvio™ (oral nalbuphine ER) is a centrally and peripherally acting investigational therapy which we are currently developing for the treatment of patients with serious chronic cough conditions including idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC).
“You’re just coughing and coughing and coughing and you get all heated up, lightheaded, feel like you want to pass out because the severity of the cough has taken so much out of you”
– Chronic Cough Patient
Kum E et al. 2022 doi: 10.1183/23120541.00667-2021
“You’re just coughing and coughing and coughing and you get all heated up, lightheaded, feel like you want to pass out because the severity of the cough has taken so much out of you”
– Chronic Cough Patient
Kum E et al. 2022 doi: 10.1183/23120541.00667-2021
Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF)
Chronic cough is highly prevalent among approximately 150,000 IPF patients in the U.S., with up to 85% of IPF patients experiencing chronic cough. The impact of chronic cough is significant and debilitating with IPF patients coughing up to 1,500 times per day and may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients’ social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients.
Refractory Chronic Cough (RCC)
Refractory chronic cough affects approximately 2-3 million adults in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is highly disruptive and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.
RCC Cough Frequency
LifeSci Capital Report Nov 2022, US (N=1000)
Cough frequency can vary from patient to patient. 73% of RCC patients report a moderate to high frequency of daily coughs and 3 out of every 4 patients remain uncontrolled leaving a large unmet need.
The most common causes of RCC are asthma, gastroesophageal reflux disease (GERD), non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip. There are no approved therapies for RCC in the U.S.